Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma

British Journal of Haematology

Volumn 170, Issue 1, 2015, Pages 131-134

  Furtado, Michelle ^a   Wang, Michael L ^b   Munneke, Brian ^c   Mcgreivy, Jesse ^c   Beaupre, Darrin M ^c   Rule, Simon ^a  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c PHARMACYCLICS INC   (United States)

Author keywords

Bone marrow; Bruton tyrosine kinase inhibitor; Ibrutinib; Lymphocytosis; Mantle cell lymphoma

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD5 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CXCL13 CHEMOKINE; IBRUTINIB; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; AGAMMAGLOBULINAEMIA TYROSINE KINASE; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; BONE MARROW; CANCER GROWTH; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; ENZYMOLOGY; LYMPHOMA, MANTLE-CELL; METABOLISM; PATHOLOGY;

BONE MARROW; HUMANS; LYMPHOCYTOSIS; LYMPHOMA, MANTLE-CELL; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84931566395     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13275     Document Type: Article

References (10)

1. Advani, R.H., Buggy, J.J., Sharman, J.P., Smith, S.M., Boyd, T.E., Grant, B., Kolibaba, K.S., Furman, R.R., Rodriguez, S., Chang, B.Y., Sukbuntherng, J., Izumi, R., Hamdy, A., Hedrick, E. & Fowler, N.H. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Journal of Clinical Oncology, 31, 88-94.
2. Burger, J.A. & Buggy, J.J. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leukemia & Lymphoma, 54, 2385-2391.
3. Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., Burger, J.A., Blum, K.A., Grant, B., Sharman, J.P., Coleman, M., Wierda, W.G., Jones, J.A., Zhao, W., Heerema, N.A., Johnson, A.J., Sukbuntherng, J., Chang, B.Y., Clow, F., Hedrick, E., Buggy, J.J., James, D.F. & O'Brien, S. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 369, 32-42.
4. Chang, B.Y., Francesco, M., De Rooij, M.F., Magadala, P., Steggerda, S.M., Huang, M.M., Kuil, A., Herman, S.E., Chang, S., Pals, S.T., Wilson, W., Wiestner, A., Spaargaren, M., Buggy, J.J. & Elias, L. (2013) Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood, 122, 2412-2424.
5. Cheson, B.D., Byrd, J.C., Rai, K.R., Kay, N.E., O'Brien, S.M., Flinn, I.W., Wiestner, A. & Kipps, T.J. (2012) Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. Journal of Clinical Oncology, 30, 2820-2822.
6. Cinar, M., Hamedani, F., Mo, Z., Cinar, B., Amin, H.M. & Alkan, S. (2013) Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leukemia Research, 37, 1271-1277.
7. Davis, R.E., Ngo, V.N., Lenz, G., Tolar, P., Young, R.M., Romesser, P.B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., Xu, W., Shaffer, A.L., Wright, G., Xiao, W., Powell, J., Jiang, J.K., Thomas, C.J., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Gascoyne, R.D., Connors, J.M., Johnson, N.A., Rimsza, L.M., Campo, E., Jaffe, E.S., Wilson, W.H., Delabie, J., Smeland, E.B., Fisher, R.I., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., Pierce, S.K. & Staudt, L.M. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 463, 88-92.
8. Gauld, S.B., Dal Porto, J.M. & Cambier, J.C. (2002) B cell antigen receptor signaling: roles in cell development and disease. Science, 296, 1641-1642.
9. Honigberg, L.A., Smith, A.M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D.H., Miller, R.A. & Buggy, J.J. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America, 107, 13075-13080.
10. Wang, M.L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B.S., Jurczak, W., Advani, R.H., Romaguera, J.E., Williams, M.E., Barrientos, J.C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W.W., Johnson, P., Spurgeon, S.E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J.J., Chang, B.Y., Beaupre, D.M., Kunkel, L.A. & Blum, K.A. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine, 369, 507-516.